

Symposium invitation

You are cordially invited to a symposium held on the occasion of the 1st International Liver Cancer Association (ILCA) annual conference

**Recent advances with targeted therapies:
a new era in the management of hepatocellular carcinoma**

Friday 5 October 2007, 18.30–19.30

Lleida/Tarragona Rooms, Princesa Sofia Hotel, Barcelona, Spain

Chair's welcome

Dear colleague,

I am pleased to invite you to a satellite symposium entitled '**Recent advances with targeted therapies: a new era in the management of hepatocellular carcinoma**', which will be held on the occasion of the inaugural International Liver Cancer Association (ILCA) annual conference in Barcelona, Spain. This symposium, which is sponsored by Bayer Schering Pharmaceuticals, will take place on Friday 5 October, 18.30–19.30.

Recent advances in our understanding of the complex underlying mechanisms of hepatocellular carcinoma (HCC) will be discussed, including an in-depth review of the molecular signalling pathways involved in the pathogenesis of HCC, discussion of the emergence of targeted therapies and the latest data from international clinical trials. The future prospects for molecular therapy of HCC will be debated by our expert panel in this interactive symposium, where audience participation will be actively encouraged.

With encouraging data reported for molecular-targeted agents, a new era in the treatment of HCC beckons. At this exciting time, I hope you will join me for what promises to be a stimulating and informative event.

A handwritten signature in black ink, consisting of a vertical line on the left and a horizontal line crossing it, with a diagonal stroke extending from the intersection towards the right.

Jordi Bruix, MD

Chair

Head of the Barcelona Clinic Liver Cancer (BCLC) Group, University of Barcelona, Barcelona, Spain

Programme

18.00 Refreshments

18.30 Symposium (Lleida/Tarragona Rooms)

Welcome and introduction

Jordi Bruix (Barcelona, Spain)

Hepatocellular carcinoma: current approaches to management

Jordi Bruix

Targeting the underlying molecular mechanisms of hepatocellular carcinoma

Gregory J Gores (Rochester MN, USA)

Management of hepatocellular carcinoma: recent advances and future prospects

Josep M Llovet (Barcelona, Spain, and New York NY, USA)

Discussion and concluding remarks

Led by Jordi Bruix

19.30 Symposium close

19.30 ILCA 2007 official welcome party



Bayer HealthCare
Bayer Schering Pharma

Bayer Schering Pharma AG, 13342 Berlin, Germany